Targeting Oxidative Stress With Auranofin or Prima-1Met to Circumvent p53 or Bax/Bak Deficiency in Myeloma Cells by Benoit Tessoulin, Benoit Tessoulin, Benoit Tessoulin, Benoit Tessoulin, Geraldine Descamps, Geraldine Descamps, Geraldine Descamps, Christelle Dousset, Christelle Dousset, Christelle Dousset, Martine Amiot, Martine Amiot, Martine Amiot, Catherine Pellat-Deceunynck, Catherine Pellat-Deceunynck, Catherine Pellat-Deceunynck

Subjects: Get full text

A thiol‐bound drug reservoir enhances APR‐246‐induced mutant p53 tumor cell death by Sophia Ceder, Sofi E Eriksson, Emarndeena H Cheteh, Swati Dawar, Mariana Corrales Benitez, Vladimir J N Bykov, Kenji M Fujihara, Mélodie Grandin, Xiaodun Li, Susanne Ramm, Corina Behrenbruch, Kaylene J Simpson, Frédéric Hollande, Lars Abrahmsen, Nicholas J Clemons, Klas G Wiman

Subjects: “…APR‐246…”
Get full text

APR-246 enhances the anticancer effect of doxorubicin against p53-mutant AsPC-1 pancreatic cancer cells by Ali Haider Alhammer, Shaymaa Ismael Al-juboori, Shahad Ali Mudhafar

Subjects: “…APR-246, Combination, Doxorubicin, Pancreatic Cancer, p53 reactivator…”
Get full text

Tumor-Associated Antigen xCT and Mutant-p53 as Molecular Targets for New Combinatorial Antitumor Strategies by Jolanda Magri, Alessandro Gasparetto, Laura Conti, Enzo Calautti, Chiara Cossu, Roberto Ruiu, Giuseppina Barutello, Federica Cavallo

Subjects: Get full text

Immunotherapy against the Cystine/Glutamate Antiporter xCT Improves the Efficacy of APR-246 in Preclinical Breast Cancer Models by Giuseppina Barutello, Antonino Di Lorenzo, Alessandro Gasparetto, Chiara Galiazzi, Elisabetta Bolli, Laura Conti, Federica Cavallo

Subjects: Get full text

APR-246 alone and in combination with a phosphatidylserine-targeting antibody inhibits lung metastasis of human triple-negative breast cancer cells in nude mice by Liang Y, Besch-Williford C, Cook MT, Belenchia A, Brekken RA, Hyder SM

Subjects: Get full text

Antitumor Effects of PRIMA-1 and PRIMA-1^Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair? by Paola Menichini, Paola Monti, Andrea Speciale, Giovanna Cutrona, Serena Matis, Franco Fais, Elisa Taiana, Antonino Neri, Riccardo Bomben, Massimo Gentile, Valter Gattei, Manlio Ferrarini, Fortunato Morabito, Gilberto Fronza

Subjects: “…PRIMA-1/APR246…”
Get full text

A combination of p53-activating APR-246 and phosphatidylserine-targeting antibody potently inhibits tumor development in hormone-dependent mutant p53-expressing breast cancer xenog... by Liang Y, Mafuvadze B, Besch-Williford C, Hyder SM

Subjects: Get full text

Neuroblastoma response to RAS-MAPK inhibitors and APR-246 (eprenetapopt) co-treatment is dependent on SLC7A11 by Vid Mlakar, Ina Oehme, Ina Oehme, Laurence Lesne, Sara Najafi, Sara Najafi, Sara Najafi, Marc Ansari, Marc Ansari, Fabienne Gumy-Pause, Fabienne Gumy-Pause

Subjects: Get full text

Targeting mutant p53 with arsenic trioxide: A preclinical study focusing on triple negative breast cancer by Subhasree Rajaram, Naoise C. Synnott, John Crown, Stephen F. Madden, Michael J. Duffy

Subjects: Get full text

Mutant p53–Nrf2 axis regulates the proteasome machinery in cancer by Kamil Lisek, Dawid Walerych, Giannino Del Sal

Subjects: “…apr-246…”
Get full text

Inhibiting system xC− and glutathione biosynthesis – a potential Achilles' heel in mutant-p53 cancers by Nicholas J. Clemons, David S. Liu, Cuong P. Duong, Wayne A. Phillips

Subjects: “…apr-246…”
Get full text